Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pharmaceutical POOL

Stanley BARSHAY
Dr. Richard BOWLES
Richard CLARK
Willie DEESE
Kenneth FRAZIER
Dr. Peter KIM
Raul KOHAN
Merck Unveils Post-Merger Organizational Structure Merck has announced its new organizational structure following the completion of its merger with Schering-Plough. The new Merck has five primary divisions: Global Human Health, Animal Health, Consumer Health Care, Merck Research Laboratories, and Merck Manufacturing. Each division and global support function leader is a member of the new Merck executive committee. Stanley Barshay, formerly chairman of consumer healthcare at Schering-Plough, is leading this business for the new Merck on an interim basis while the company searches for a permanent leader. The consolidated company plans to place an increased emphasis on growing the consumer business, particularly in markets outside the United States. Richard Bowles III, Ph.D., formerly senior VP of global quality operations at Schering-Plough, is serving as chief compliance officer for the new Merck. Mr. Bowles helps to ensure that the new Merck leads on ethics and compliance through central leadership and management of these activities. As announced in March 2009, Merck Chairman, President, and CEO Richard Clark has been appointed CEO of the new Merck. Willie Deese, executive VP and president of the Merck Manufacturing division (MMD), has been named to lead the new MMD, which includes new units for consumer health and animal health, as well as expanded technological capabilities for vaccines and biologics. The new MMD is creating a strong, interdependent global supply chain fully focused on the needs of the combined company’s customers. Kenneth Frazier, formerly executive VP and president of Global Human Health (GHH) for Merck, has been tapped to lead the new GHH organization, which includes the company’s prescription, vaccines, and biologics businesses. A new emerging markets group also is part of the new GHH organization and charged with focusing on regions and markets around the world that represent significant new growth opportunities, including Asia-Pacific, particularly China; Latin America; and the Middle East/Africa/Eastern Europe, including Russia and Turkey. The new Merck Research Laboratories (MRL) is led by Peter S. Kim, Ph.D., formerly executive VP and president of MRL. The new structure for MRL is designed to foster innovation while instilling greater accountability at all stages of the R&D process, and has a new central franchise structure focused on portfolio management that is aligned with the company’s GHH division. The combined research organization has three new areas of dedicated focus — emerging markets, vaccines, and biologics — to build on the significant investments that both Merck and Schering-Plough have made in this area. Raul Kohan, formerly senior VP and president of Intervet Schering-Plough Animal Health, has been appointed to lead the new Merck’s animal health business. Bryce CARMINE Enrique CONTERNO Dr. Tim GARNETT John JOHNSON David RICKS Jeffrey SIMMONS Jacques TAPIERO Dr. Tom VERHOEVEN Eli Lilly Shifts Operating Model Eli Lilly has announced a new operating model to speed innovative medicines to patients. As part of this new model, the company has named the leaders of its Development Center of Excellence and its five business units: oncology, diabetes, established markets, emerging markets, and Elanco animal health. Bryce Carmine, Lilly’s executive VP of global marketing and sales, has been appointed to lead the established markets business unit. This unit encompasses Lilly’s important therapeutic areas outside of diabetes and oncology, including neuroscience, osteoporosis/bone, and cardiovascular, and has geographic responsibility for these therapeutic areas in the United States, Japan, the European Union, Canada, and Australia/New Zealand. The established markets area also hosts Lilly’s global marketing organization. Mr. Carmine joined Lilly in 1975 in New Zealand before moving to the company’s headquarters in Indianapolis in 1983. Enrique Conterno, president of Lilly USA, has been tapped to lead the diabetes business unit. Lilly has long been a leader in diabetes care, with a dedicated asset base and a portfolio of commercially successful products and promising pipeline opportunities. Mr. Conterno joined the company in 1992 as a sales rep. He earned an MBA from Duke University. Tim Garnett, M.D., co-leads the Development Center of Excellence (COE) within Lilly Research Laboratories, with responsibility for medical, regulatory, global product safety, translational medicine, and global health outcomes. With more than 60 molecules in clinical development, the Development COE is tasked with streamlining the development of pipeline molecules and speeding innovative medicines to patients. Dr. Garnett is currently chief medical officer and senior VP of global medical, regulatory, and safety for Lilly. He qualified in medicine at St. George’s Hospital in London and practiced obstetrics and gynecology for eight years before joining the pharmaceutical industry. He is a fellow of the Royal College of Obstetricians and Gynecologists in the United Kingdom and a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians, as well as a member of the Royal Society of Medicine. John Johnson leads the oncology business unit. Mr. Johnson currently serves as CEO of ImClone Systems, a wholly owned subsidiary of Lilly. With the acquisition of ImClone and the progression of its own pipeline, Lilly remains intent on building an oncology powerhouse. David Ricks succeeds Mr. Conterno as president of Lilly USA. A 13-year Lilly veteran, Mr. Ricks most recently served as general manager of Lilly China. Mr. Ricks received a marketing and finance MBA from Indiana University. Jeffrey Simmons has been selected to lead Elanco, the animal health business unit, where he currently serves as president. Elanco sales continue to grow at a rate faster than the overall animal health market; the business is positioned to deliver double-digit earnings growth over the next five years. Mr. Simmons joined Lilly in 1989 in sales. Jacques Tapiero, Lilly’s president of the intercontinental region, is leading the emerging markets business unit. This unit includes many of the world’s fastest-growing markets, such as China, Russia, Brazil, Mexico, South Korea, and Turkey. Lilly aims to increase its presence in these countries and other emerging markets. Mr. Tapiero also is a member of the company’s senior management council. He received an MBA from the Ecole Superieure de Commerce at Clermond Ferrand in France, and a second MBA from Thunderbird, the American Graduate School of International Management. Tom Verhoeven, Ph.D., co-leads the Development Center of Excellence within Lilly Research Laboratories, with responsibility for the clinical development organization, product R&D, toxicology/ADME, and project management. Dr. Verhoeven joined Lilly as VP for product research and development in 2003 and was promoted to senior VP of global product development in 2008. He received a doctorate in organic chemistry from the University of Wisconsin and an appointment as a National Institutes of Health (NIH) fellow at Stanford University. Elizabeth CERMAK J&J Veteran Joins Pozen as Commercial Chief Pozen, a pharmaceutical company focused primarily on products for the treatment of migraine, acute and chronic pain, and other pain-related conditions, has appointed Elizabeth Cermak executive VP, chief commercial officer. Ms. Cermak is responsible for the development and implementation of Pozen’s commercialization strategy for all of its future product candidates, including the PA family of products. Ms. Cermak joins Pozen after 25 years at Johnson & Johnson, where she most recently served as worldwide VP personal products franchise, Johnson & Johnson Healthcare Products. She received an MBA from Drexel University. Biotechnology POOL Dr. Dennis MILLER ZymoGenetics Promotes Research VP ZymoGenetics, a biotechnology firm focused on the creation of novel protein drugs to improve patient care and address unmet medical needs, has promoted Dennis Miller, Ph.D., to senior VP of research and preclinical development, from his previous role as VP, preclinical development. Dr. Miller has been with ZymoGenetics since 2005. Dr. Miller received a Ph.D. in biochemistry from Utah State University and completed a postdoctoral fellowship at the University of Washington in the Department of Environmental Health. Dr. Ram NIMMAGUDDA Spherix Names Business Development Head Spherix has appointed Ram Nimmagudda, Ph.D., director of new business development, with responsibility for developing new business opportunities for both of Spherix’s wholly owned subsidiaries: Spherix Health Sciences Consulting, a provider of technical and regulatory consulting services to food, supplement, biotechnology, and pharmaceutical companies; and Biospherix, a biotechnology firm with a focus on diabetes therapy innovation. Most recently, Dr. Nimmagudda served as director of new business development, South Asia, for DSM Functional Foods. He received an M.S. in biochemistry from Mysore University and a Ph.D. in biochemistry from Mangalore University, both in India. Dr. Clet NIYIKIZA Former GlaxoSmithKline VP Joins ­Merrimack Pharmaceuticals Merrimack Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease, has appointed Clet Niyikiza, Ph.D., senior VP, development. Dr. Niyikiza joins Merrimack from GlaxoSmithKline, where he was VP and medicine development leader for oncology. He received a master’s degree and a doctorate from Indiana University and a master’s degree from the African Institute of Statistics and Applied Economics in Kigali, Rwanda. Aaron WHITEMAN GENova Biotherapeutics Appoints CEO GENova Biotherapeutics, a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, has named Aaron Whiteman CEO. Mr. Whiteman has extensive experience in team building and negotiation with pharma companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec. Before joining GENova, he served as a VP (elect) for a number of Asian medical research project companies, responsible for business development and expansion into the European, Middle Eastern, and African regions. Biopharmaceutical POOL Mark BOOTH Former Takeda Pharma President Joins Orexigen as Commercial Chief Orexigen Therapeutics, a biopharmaceutical company focused on the treatment of obesity, has appointed Mark Booth chief commercial officer. Mr. Booth brings more than 25 years of commercial and business development experience to Orexigen. Most recently, Mr. Booth served as president of Takeda Pharmaceuticals North America. He holds an MBA from Northwestern University’s Kellogg School of Management. Dr. Hubert CHEN Regulus Selects VP of Translational Medicine Regulus Therapeutics, a biopharmaceutical company focused on microRNA therapeutics, has named Hubert Chen, M.D., VP of translational medicine. Dr. Chen is responsible for leading the translation of the important biological discoveries in the field of microRNA therapeutics into new medicines. Before joining Regulus, Dr. Chen was senior director of clinical research at Amylin Pharmaceuticals. He received an M.D. from Columbia University and performed postdoctoral research at Gladstone Institute of Cardiovascular Disease. John DOYLE Achaogen Chooses Selects Operating Chief Achaogen has appointed John Doyle to the newly created position of chief operating officer. Mr. Doyle joins Achaogen from Genentech, where he served as VP of finance and corporate planning. He received an MBA from the Haas School of Business at the University of California, Berkeley. Achaogen is a clinical-stage biopharmaceutical company addressing the issue of multidrug-resistant bacterial infections through the discovery and development of innovative, broad-spectrum antibiotics, Dr. Jan FAGERBERG Micromet Appoints Chief Medical Officer Micromet, a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation, and autoimmune diseases, today has appointed Jan Fagerberg, M.D., Ph.D., as senior VP and chief medical officer. Dr. Fagerberg is a board-certified clinical oncologist with more than 20 years of experience in clinical research and development of oncology drugs. He joins Micromet from TopoTarget, where he was medical director responsible for the pivotal clinical development program for belinostat for the treatment of peripheral T-cell lymphoma. Dr. Fagerberg received an M.D. from the Karolinska Institute in Stockholm and a Ph.D. for work in clinically applied passive and active immunotherapy targeting EpCAM in colorectal carcinomas. Dr. Edward HARLOW Jr. Constellation Pharmaceutical Names ­Scientific Chief Constellation Pharmaceuticals has named Edward Harlow Jr., Ph.D., chief scientific officer. Dr. Harlow’s responsibilities include the direction of the company’s research and drug discovery efforts, initially focused on new treatments for cancer. Constellation is a biopharmaceutical company dedicated to the development of novel therapeutics in the emerging field of epigenetics, a new field of science that focuses on selective regulators of gene function and expression. Dr. Harlow is a distinguished molecular biologist and internationally recognized leader in cancer biology best known for his discoveries around the control of cell division and critical changes that allow cancer to develop. He most recently served as professor and chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and associate director of the Dana-Farber/Harvard Cancer Center. Dr. Harlow received an M.S. from the University of Oklahoma and a Ph.D. from the Imperial Cancer Research Fund in London. Henry HEINSOHN Dr. Lesley STOLZ Sutro Announces Management ­Appointments Sutro Biopharma, a biopharmaceutical company that uses its open cell-free synthesis (OCFS) technology for the discovery and production of novel biomedicines, has added two VPs to its leadership roster. Sutro has named Henry Heinsohn VP of development and manufacturing. Mr. Heinsohn was formerly Genentech’s senior scientist and senior group leader for process development, early stage purification activities. Lesley Stolz, Ph.D., has joined Sutro as VP of business development. Dr. Stolz was previously VP, corporate and business development for Sunesis Pharmaceuticals. She received an M.S. and a Ph.D. from the University of Rochester and conducted postdoctoral research at Harvard Medical School’s department of biochemistry and molecular pharmacology. Dr. William SLICHENMYER Aveo Hires Medical Chief William Slichenmyer, M.D., Sc.M., has joined Aveo Pharmaceuticals as chief medical officer. Aveo is a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop, and commercialize targeted oncology therapies. Dr. Slichenmyer has 15 years of experience leading the clinical development of novel cancer therapeutics at a number of biopharmaceutical companies, most recently as chief medical officer for Merrimack Pharmaceuticals. He received an M.D. from Case Western Reserve University and did postgraduate training in pathology and internal medicine. Dr. Slichenmyer also underwent subspecialty training in medical oncology at the Johns Hopkins Oncology Center, where he also earned a master’s degree in clinical investigation. Peter WILLIAMS ImmunoGen Appoints Business Development VP ImmunoGen, a biopharmaceutical company that develops targeted anticancer therapeutics, has appointed Peter Williams VP, business development. Mr. Williams was most recently senior director of business development for Alnylam Pharmaceuticals. He received a master of science in management science (accredited MBA) from the Imperial College of Science, Technology & Medicine, University of London in the United Kingdom. Specialty POOL Dave IWANICKI EKR Therapeutics Creates Corporate Development VP Role EKR Therapeutics, a privately held specialty pharmaceutical company focused on acquiring, developing, and commercializing novel acute-care products, has appointed of Dave Iwanicki as senior VP, corporate development. Mr. Iwanicki was previously senior VP, commercial operations for EKR. In his new role, Mr. Iwanicki spearheads EKR’s broadening corporate development activities, including the identification and evaluation of new growth opportunities. Stephen TURNER Scolr Pharma Announces Leadership Change Specialty company Scolr Pharma has promoted Stephen Turner to succeed Bruce Morra, Ph.D., as CEO and president. Dr. Morra continues to serve as a company director. Mr. Turner has been VP and chief technical officer of Scolr since 2003 and has been instrumental in development of the company’s proprietary controlled delivery technology (CDT). Scolr focuses on combining its formulation expertise and its CDT platform to develop novel pharmaceutical, over-the-counter, and nutritional products. G. Frederick WILKINSON Former Duramed President Joins Watson as Global Brands VP Watson Pharmaceuticals, a generic and specialty branded pharmaceuticals firm, has named G. Frederick Wilkinson executive VP, global brands. In this newly expanded position, Mr. Wilkinson’s responsibilities include brand product development, global sales and marketing, and coordinating brand product business development activities. In addition, Mr. Wilkinson oversees Watson’s biologic development efforts. Most recently, Mr. Wilkinson served as president and chief operating officer of Duramed Pharmaceuticals, the proprietary products subsidiary of Barr Pharmaceuticals. Association POOL Paul POMERANTZ DIA Selects New Executive Director The Drug Information Association (DIA) has named Paul Pomerantz worldwide executive director. Mr. Pomerantz directs the DIA’s global operations and strategic expansion and leads the implementation of the board of directors’ long-term plan for sustainability and growth. He replaces William Brassington, who has served as acting executive director since July 2008. Mr. Brassington resumes his role as worldwide director of finance at the DIA. Mr. Pomerantz brings to the DIA more than 25 years of healthcare experience with specialized expertise in medical society management and hospital administration. He most recently served as executive VP of the American Society of Plastic Surgeons (ASPS). Diagnostic POOL Christopher BUNTING Avid Radiopharmaceuticals Appoints ­Marketing VP Avid Radiopharmaceuticals has appointed Christopher Bunting VP, marketing and sales, with responsibility for the commercialization of AV-45, an F-18 compound in development for imaging amyloid plaque in the brain associated with Alzheimer’s disease. Mr. Bunting has more than two decades of marketing and sales experience, most recently as global brand director for neurology at United Kingdom-based General Electric Healthcare. Avid develops molecular imaging products with the potential for earlier and more effective detection, diagnosis, and monitoring of major chronic human diseases. Emerging POOL Michael COFFEE Dr. Amy PATICK Adamas Expands Management Team Adamas Pharmaceuticals, a privately held emerging pharmaceutical company focused on developing small-molecule therapeutics to treat neurological and infectious diseases, has named Michael Coffee senior VP, sales and marketing. In addition, Mr. Coffee’s responsibilities include identification of ex-U.S. partners and new product initiatives. His initial focus is on developing international partnerships for Adamas’ infectious disease and CNS programs, as well as developing the specialty pharmaceutical business unit. Mr. Coffee was most recently chief business officer for Avigen. As the newly appointed VP, research for Adamas, Amy Patick, Ph.D., is responsible for activities aimed at establishing proof-of-concept of Adamas’ infectious disease and neurology drug development programs. Dr. Patick also leads the company’s efforts to build its scientific presence and collaborations with anti-infective and CNS community leaders. Dr. Patick was previously VP, biological sciences for Genelabs Technologies. She received a Ph.D. in medical microbiology from the University of Wisconsin and had postdoctoral training at the Mayo Clinic. She is the current president of the International Society for Antiviral Research. Agency POOL Laurie BARTOLOMEO Scott HARPER Heather WAGONER Staff Changes at Dudnyk Dudnyk, a full-service healthcare marketing and medical advertising agency, has promoted Laurie Bartolomeo to associate creative director, copy. Ms. Bartolomeo is responsible for pursuing new business opportunities and supervising copy efforts for several Dudnyk clients, as well as continuing to work on product launches for clients in the prescription, biotech, medical device, and diagnostic industries. She received an M.S. in teaching from Rowan University. Dudnyk also has added two members to its account services team. Scott Harper has joined Dudnyk as account group supervisor. Mr. Harper was previously an account supervisor with GSW Worldwide. Heather Wagoner has joined Dudnyk as account executive from the same position at Dorland Global. Neal BELLUCCI Natalie BROADBENT Andrea GASPARO Florence LEVITT Nicole RAMOCKI Dave RAUCH Carla RILEY Kate SARNA Laura STANDAFER Elissa THORNE Andrea TRBOVICH Nancy WALSH GSW Announces New Hires Global healthcare advertising agency GSW Worldwide, an inVentiv Health company, has made a number of appointments to its offices in New York, Columbus, Ohio, and Newtown, Pa. Neal Bellucci has been named senior editor for the Newtown office. Previously, Mr. Bellucci served as editor for Wyeth Pharmaceuticals. Natalie Broadbent has been named account supervisor in the Columbus office. Before joining GSW, Ms. Broadbent was marketing manager for Worthington Cylinders. Andrea Gasparo has been named senior account executive. Ms. Gasparo most recently worked for Health Science Communications as senior program director. She holds a master’s degree from New York University. In New York, Florence Levitt has been named VP, associate creative director. Ms. Levitt was previously senior VP, creative director for DraftFCB Healthcare. Nicole Ramocki joins the Newtown office as medical strategist. Ms. Ramocki was most recently medical writer for MedErgy Group. She received a doctorate from University of North Carolina. Dave Rauch has been named director, digital ideation, for the New York office. Mr. Rauch joins GSW from DraftFCB, where he was creative director. In Columbus, Carla Riley has been appointed senior editor. Previously, Ms. Riley was production editor with McGraw-Hill. Kate Sarna has joined the Columbus office as senior account executive. Ms. Sarna was most recently senior marketing associate for PharMEDium Services. Laura Standafer has been named account executive in the Columbus office. Before joining GSW, Ms. Standafer served as media specialist for Wendy’s International. Elissa Thorne has been named digital designer for the Newtown office. Ms. Thorne was previously marketing coordinator for Time Value Property Exchange. She holds a master’s degree from Northeastern University. Andrea Trbovich has been appointed senior editor for the Columbus office. Previously, Ms. Trbovich was managing editor for RBMA Bulletin. In Newtown, Nancy Walsh has been named senior account executive. Ms. Walsh previously served as senior account executive for Compass Healthcare Communications. Elisha BURY Dr. Olivia LEE Cadent Expands Editorial Staff Cadent Medical Communications, an inVentiv Health company, has made two editorial hires. Elisha Bury has been named biomedical editor. Ms. Bury was most recently editor for 1105 Media. Olivia Lee, Ph.D. has joined Cadent as medical writer. She earned a doctorate from University of Texas Southwestern Medical Center. Maryanne KELLEHER Karen LANGENBERG Dan WEATHERBY Stonefly Announces Staff Additions Healthcare advertising agency Stonefly Communications Group, an inVentiv Health company, has made three new appointments to its team of marketing and design professionals. Maryanne Kelleher has been named VP, account director, with responsibility for leading major agency accounts, mentoring junior staff members, and building and overseeing existing and new client relationships. Ms. Kelleher has nearly two decades of pharmaceutical marketing experience, including positions with inVentiv Health’s Creative Healthcare Solutions, Sanofi-Aventis, and Johnson & Johnson Consumer Products. Karen Langenberg joins Stonefly as VP, medical marketing insights. As part of the agency’s leadership team, Ms. Langenberg is responsible for Stonefly’s insight planning and scientific and medical direction. She previously served as senior director for medical science at OSI Eyetech. Dan Weatherby has been appointed director, interactive design and strategy, with responsibility for providing creative and strategic development and direction for Stonefly’s digital offering. Mr. Weatherby has more than 15 years of digital design and strategic development experience, most recently as director of interactive design and technology for People to My Site. Richard LEV Former Roche Executive Joins PSSG Publicis Strategic Solutions Group (PSSG), a provider of multichannel message delivery solutions for the life-sciences industry, has named Richard Lev, J.D., chief compliance officer. PSSG is a division of Publicis Healthcare Communications Group. Mr. Lev oversees the corporate compliance program, which reviews and evaluates all compliance issues and concerns within the organization. He most recently served as senior counsel for Roche. Mr. Lev holds a J.D. from the Benjamin N. Cardozo School of Law, Yeshiva University. Sanjay PINGLE Medsite Co-founder Joins Physicians ­Interactive as President Physicians Interactive (PI), a provider of digital sales and marketing solutions for life-sciences companies, has appointed Medsite Co-founder Sanjay Pingle president. Mr. Pingle’s responsibilities at PI include leading the company’s pharmaceutical business unit, as well as spearheading growth of the digital sales and marketing business. He is working to develop new digital marketing tools, products, and services that integrate lines of business to further enhance customers’ ability to effectively reach and support healthcare professionals. Following the sale of Medsite to WebMD in 2006, Mr. Pingle went on to serve as VP at WebMD. Most recently, he co-founded Terasol Energy, a renewable energy business focused on seed technology in Brazil. Claire PISANO Deborah REALE Solara Expands Editorial, Account Teams Solara, a CommonHealth business unit created to provide strategic marketing services to improve patient access to pharmaceutical brands competing in managed markets, has announced two new hires. Claire Pisano joins Solara as an account executive. Most recently, Ms. Pisano had been an intern working part time at Solara. Deborah Reale has been named senior editor. Ms. Reale was previously the managing editor of Contemporary Surgery. CRO POOL Scott CLARK Quanticate Selects Head of U.S. ­Business Development Quanticate, a global biometrics CRO, has named Scott Clark as head of business development for its clinical trials services and operations based in Cambridge, Mass. The appointment enhances the company’s mission to further expand its clinical trial service capabilities, with Mr. Clark managing the company’s U.S. business development initiatives in support of existing and new clients. Before joining Quanticate, Mr. Clark served as VP and global head of Quintiles’ e-solutions business. Dr. Deborah COVINGTON PPD Appoints Head of Observational Studies Global CRO PPD has named Deborah Covington, Dr.PH., as global head of observational studies and pregnancy registries. Dr. Covington provides leadership and direction to the company’s late-stage group and serves as a member of the strategic and scientific advisory team. Her appointment follows the global expansion of the company’s late-stage research services, which include Phase IIIb-IV clinical trials, epidemiology, registries, observational studies, and safety surveillance studies. Dr. Covington has more than 30 years of clinical research experience in epidemiology, maternal, and child health. Before joining PPD, she spent eight years with another global CRO where she provided scientific guidance and oversight of registries and epidemiology. Dr. Covington has served as a consultant to the World Health Organization in planning pregnancy registries for malaria and HIV in Africa. Dr. Covington earned a master’s degree in sociology from the Virginia Polytechnic Institute and State University and a doctorate in public health from the University of North Carolina at Chapel Hill. Dr. Patricia Taylor MOLLOY Dr. Michael SKINNER Premier Research Expands Medical Affairs Group International pharmaceutical and medical device services company Premier Research Group has appointed two physicians to its medical affairs and strategic consulting group, enhancing the company’s expertise in the areas of neurology, oncology, pediatrics, and analgesia. Patricia Taylor Molloy, M.D., has joined Premier Research as VP, global medical affairs and strategic consulting, with responsibility for global oversight of medical affairs and strategic consulting. Dr. Molloy was most recently senior medical director, oncology and neurology, for Cephalon. She is a board certified neurologist with a fellowship in neuro-oncology. Michael Skinner, M.D., Pharm.D., has been appointed an executive director, medical affairs and strategic consulting. Dr. Skinner provides consulting, strategic development, and medical monitoring services in the areas of internal medicine and analgesia. He was previously senior medical director at Somaxon Pharmaceuticals and VP, clinical development, at Allergan. He is board-certified in internal medicine and clinical pharmacology with fellowships clinical pharmacology and substance abuse. Brett TRUITT Xcelience Names Formulation Team ­Leader Xcelience, a CRO focused on early drug development services, has appointed Brett Truitt team leader, formulation development in its pharmaceutical development services division. Mr. Truitt has more than a decade’s worth of experience in pharmaceutical research and formulation development, having held various research and development positions at Bilcare Global Clinical Supplies, Shire Laboratories/Supernus Pharmaceuticals, Pfizer, and Procter and Gamble. Media POOL Kelly ADAMITIS Peter MESSINA Lippincott Williams & Wilkins Makes Sales Appointments Wolters Kluwer Health has promoted Kelly Adamitis to advertising sales director for medical journals for its Lippincott Williams & Wilkins (LWW) publications business. Wolters Kluwer Health is a provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, pharmacy, and the pharmaceutical industry. Mr. Adamitis oversees the American Academy of Neurology (AAN) publications, including the flagship research journal Neurology, the specialty news magazine, Neurology Today, and the patient magazine Neurology Now. His assignment also includes other prestigious LWW publications across a wide range of specialties, such as Obstetrics & Gynecology, Emergency Medicine News, Anesthesiology, and Spine. Peter Messina has accepted a position on the advertising sales team for medical journals for LWW. Mr. Messina has assumed sales responsibilities for the AAN portfolio and a number of other LWW journals, including American Journal of Geriatric Psychiatry and Journal of Developmental and Behavioral Pediatrics. He joins LWW from the American Medical Association’s Archives Journals, where he held various sales and account management positions. Service POOL Kristine ANTHONY Robyn HARNESS Scientific Voice Bolsters Accounts Team Scientific Voice, a provider of biopharma speaker bureau and program management services, has made two new appointments to its accounts team. Kristine Anthony has been named account director. Previously, Ms. Anthony was client service manager at Advogent, formerly known as Cardinal Health. Robyn Harness has joined Scientific Voice as a senior account leader. Ms Harness was most recently director of operations and practice leader at Euro RSCG. Patrick BLAKE Mark WALCHIRK McKesson Promotes Unit Presidents Patrick Blake has been promoted to executive VP and group president at McKesson, with overall responsibility for McKesson’s technology solutions segment. Mr. Blake holds an MBA from the Graziadio School of Business and Management at Pepperdine University. Mark Walchirk succeeds Mr. Blake as president of McKesson Specialty Care Solutions, a business unit of McKesson that delivers services to pharmaceutical and biotech manufacturers and specialty providers, including oncologists, to ensure specialty pharmaceutical products, coordinated reimbursement, and clinical services are available to patients with complex diseases. Most recently, Mr. Walchirk served as senior VP and chief operating officer, McKesson U.S. Pharmaceutical. David DEUTSCH Dave DORNSTREICH TargetRx Expands Management Team TargetRx has added two VPs to its executive roster to support the expansion of the company’s customer base and lead the development of new pharmaceutical sales and marketing effectiveness solutions. David Deutsch has been named VP of client service and development. Mr. Deutsch joins TargetRx from IMS Health, where he served as senior principal and oncology thought leader. He received an MPH in health services management from Johns Hopkins University. Dave Dornstreich has joined TargetRx as VP of business development. Mr. Dornstreich most recently served as VP of sales for i3 Pharma Informatics. Anita GURAK Rhonda LEVINSON Publicis Selling Solutions Adds Staff Publicis Selling Solutions, a provider of sales, service, and clinical teams for biopharma companies, has made two additions to its staff. Publicis Selling Solutions is a Publicis Strategic Solutions Group company. Anita Gurak has joined Publicis Selling Solutions as business development manager. Ms. Gurak was formerly a urology sales specialist for Allergan. Rhonda Levinson has been named client services director. She was previously director of client services at Total Health Rewards. Donald OTTERBEIN John WALSH IMS Health Promotes Two IMS Health has tapped Donald Otterbein to fill the new role of general manager, business transformation services, as part of the global market intelligence provider’s extension of its knowledge process outsourcing capabilities. Mr. Otterbein’s new responsibilities include leading the company’s growth in commercial analytics outsourcing of pharmaceutical clients’ sales, marketing, and managed markets activities. He was most recently responsible for developing and delivering IMS Health’s information offerings in the Americas region, as well as for statistical services, client services activities, and ongoing quality initiatives. In other moves, IMS Health has promoted John Walsh to senior VP, payer and government solutions, from senior VP, strategy and business development. In this newly created position, Mr. Walsh is responsible for the continued expansion of IMS’s payer and government solutions initiatives in markets worldwide, as well as leading the company’s comparative effectiveness research activities. He received an MBA from the University of Chicago. Anthony SORCE Jeff WOJCIK TGaS Advisors Selects Business Development VP TGaS Advisors, a provider of benchmarking and advisory services to the pharmaceutical industry, has appointed Anthony Sorce VP for new business development. Mr. Sorce was previously VP, pharmaceutical sales, at Thomas Reuters Healthcare. He earned an MBA in marketing at Fairleigh Dickinson University. TGaS has also announced the promotion of Jeff Wojcik to principal in recognition of the important contributions he has made to the company while serving as VP and management advisor responsible for a key business segment. Technology Pool Miki STEVENS ERT Appoints Business Development Director for Japan ERT, a provider of centralized ECG, ePRO, and other services to the biopharmaceutical, medical device, and related industries, has named Miki Stevens associate director of business development — Japan. In Ms. Stevens is working with ERT’s Japanese partner, Site Support Institute (SSI), to facilitate sales activities and enhanced in-country support of Japanese sponsors and clinical-trial sites. Ms Stevens joins ERT from Parexel International (Tokyo), where she worked as an account manager in business development. F Send your personnel announcements to feedback@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK